JAHA: Corticosteroid and immunosuppressive therapy for cardiac sarcoidosis

Clinically, corticosteroids are usually recommended to treat cardiac sarcoidosis with clinical symptoms
.

Recently, the heart blood vessels published on the prestigious journal JAHA the areas of disease research article, the researchers reviewed 2013 data systematically; since then, the quality and quantity of data continues to increase, people are also increasingly non-steroidal drugs The more interested

Heart blood vessels

 
The researchers identified the required studies from the MEDLINE, EMBASE, Cochrane Controlled Trials Register, the Cochrane Systematic Review Database and the National Institutes of Health ClinicalTrials.

gov database, and used the Scottish Intercollegiate Guidelines Network50 to rate the quality of the included studies

The researchers retrieved a total of 3,527 references, 34 of which met the inclusion criteria
.

There were no randomized trials in the included studies, and only 2 studies were rated as high-quality studies

immunity

In contrast, 21 patients did not receive corticosteroids and/or immunosuppressive therapy, but none of them improved
.

Corticosteroid treatment is related to the prevention of deterioration of left ventricular function

Prevention of corticosteroids and/or immunosuppressive therapy in patients with cardiac sarcoidosis in both cases with atrioventricular nodal conduction and recovery of left ventricular function are associated with positive outcomes

Original source:

Siavosh Fazelpour.

et al.
Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review .
JAHA.
2021.